Progression-free survival of NLPHL and cHL patients from the HD16 study according to the iPET result. (A) PFS of patients with NLPHL (red) and those with cHL (blue) from the HD16 study with a positive iPET result. (B) PFS of patients with NLPHL (red) and those with cHL (blue) from the HD16 study with a negative iPET result. (C) PFS of patients with NLPHL from the HD16 study with a negative iPET result who had chemotherapy alone (red) or combined-modality treatment (blue).